Drug-Drug Interaction SIG

Established October 2019

Overview and Mission

Pharmacoepidemiologic studies are essential to confirm (or refute) and elucidate the health effects of potential drug-drug interactions (DDIs). In addition to applying principles for good pharmacoepidemiology practice, researchers conducting DDI studies must consider nuances in design and interpretation that follow from a focus on the health effects of combinations of multiple exposures rather than single medical products. The DDI Special Interest Group will serve as a collaborative community of ISPE members with an interest in the design, analysis, interpretation, and translation of pharmacoepidemiologic studies of drug interactions.


  • To provide a diverse collaborative forum for persons around the world interested in real-world DDI research
  • To improve the quality of real-world DDI research that informs the clinical evidence base
  • To foster the development of new pharmacoepidemiologic methods to study DDIs
  • To educate the general ISPE membership and external stakeholders on the role of pharmacoepidemiology in studying DDIs
  • To promote the professional development of junior ISPE members interested in DDI research
  • To facilitate the translation of high-quality real-world DDI studies into clinical practice

Please visit our ISPE Community for the latest SIG news, upcoming meetings, membership, documents library, connecting with SIG members and leaders, and more. An account is needed to access the community and join it.

SIG leader(s)

Chair Cheng (Alice) Chen
Vice Chair John Hughes